Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Principia gets $50mm through Series B round; round closes at $65.9mm

Executive Summary

Principia BioPharma Inc. (small-molecule therapeutics for autoimmune diseases, inflammation, and oncology) raised $50mm through its Series B round. Sofinnova Ventures led (and takes a board seat) and was joined by all of Principia’s existing investors, including Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One, Mission Bay capital, and others. Proceeds will fund advancement of the company’s preclinical pipeline, comprised of an oral BTK inhibitor for autoimmune disease and cancer, an oral selective FGFR inhibitor for solid tumors, and an IL-17 pathway inhibitor for a variety of autoimmune and inflammatory diseases.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies